Researchers at Hunter College and the CUNY Graduate Center have identified potential anticancer activity in laboratory-made derivatives of cannabichromene (CBC), a naturally occurring cannabis compound.
The study, published October 23, 2026, in the Journal of Natural Products, examined 10 new molecules chemically modified from CBC. These derivatives do not naturally occur in cannabis.
Two Compounds Showed Strong Activity Against Cancer Cells
All 10 compounds were screened at a single concentration of 10 micromolar (µM) using the National Cancer Institute's NCI-60 panel of human tumor cell lines.
Two compounds, numbered 8 and 9, demonstrated the broadest and strongest growth-inhibiting activity.
Their effects were generally comparable in magnitude to historical paclitaxel results in the NCI database. However, this laboratory comparison does not establish that the compounds would work as cancer treatments.
One Compound Reduced Prostate Cancer Cell Growth
Researchers selected compound 9 for additional dose-response testing.
The concentration required to reduce cell growth by 50% (GI50) was:
• PC-3 prostate cancer cells: 2.01 µM • DU-145 prostate cancer cells: 1.86 µM • Average across the tested panel: approximately 4.07 µM
Compound 9 also increased apoptosis, or programmed cell death, in both prostate cancer cell lines after 48 hours. The effect increased with dose, and DU-145 cells were more sensitive.

These Results Do Not Establish a Cancer Treatment
Every experiment was conducted in cultured cancer cells. Researchers did not test the compounds in animals or humans.
The study also did not identify a molecular target. The authors described the activity as apparently non-selective, meaning the compounds inhibited growth across multiple cell lines rather than demonstrating a specific cancer-targeting mechanism.
Importantly, natural CBC itself was not the tested anticancer agent. It served as the starting material for creating the new molecules.
The findings represent an early drug-discovery result, not evidence that CBC or its derivatives can treat cancer in people. Comprehensive follow-up research is needed before any medical application can be considered.
Remedy Processors LLC, a cannabis company, partially funded the research and supplied the CBC. Screening was conducted through the National Cancer Institute's Developmental Therapeutics Program.
Read next
Sources
- Patra, Namballa, Okpattah, Gudipally & Harding. Journal of Natural Products, 89(10):2827–2836, October 23, 2026. DOI: 10.1021/acs.jnatprod.6c00722. PMID: 42924954. Reports the synthesis of 10 CBC-derived compounds, NCI-60 screening results, dose-response measurements and laboratory apoptosis findings.


0 comments